Why Cleanrooms Are Transitioning To Offsite
Offsite construction is one of the key drivers in a global cleanroom market that is expected to grow by a steady 6.6% CAGR to a value of $5.7 billion in 2024.
Across all sectors, including pharma, biotechnology, cell gene therapy and semi-conductor manufacture, there is a recognition that innovation in offsite construction and manufacturing has the potential to deliver the combination of value and the increased agility required in this era of pandemic.
Advances in offsite design and manufacturing processes create precision-engineered solutions that meet the stringent quality standards demanded in cleanrooms. These advances, combined with pressure on the industry to improve efficiency, reduce operating costs and speed up the drug and therapy development and manufacture and are significant factors in the transition to cleanrooms now being manufactured offsite.
Offsite construction facilitates the implementation of best practice in a controlled environment while improving the delivery of key project fundamentals. There are measurable cost benefits in reduced construction time and greater precision and quality from manufacturing in purpose-built fabrication centres rather than construction site conditions.
There are currently around 8,000 bio/pharmaceutical cleanrooms in the ISO 5-9 range in use with growth estimates for 11,000 by 2025 and 15,000 by 2030. Offsite manufacturing will play a crucial role in that growth.